@Article{or.2025.065050,
AUTHOR = {Hailong Li, Wen Ouyang, Yiyin Long, Yun Peng, Ziyi Liu, Qi Zhou, Rong Xu, Wei Du},
TITLE = {MRPL18 Promotes Breast Cancer Progression: Connecting Mitochondrial Ribosomal Protein to Immune Response},
JOURNAL = {Oncology Research},
VOLUME = {33},
YEAR = {2025},
NUMBER = {9},
PAGES = {2549--2571},
URL = {http://www.techscience.com/or/v33n9/63633},
ISSN = {1555-3906},
ABSTRACT = { <b>Background:</b> The study aimed to explore the clinical value of mitochondrial ribosomal protein L18 (MRPL18) in breast cancer. <b>Methods:</b> Multiple databases were used to validate the expression of MRPL18. The prognostic impact and predictive value of MRPL18 were evaluated by using predictive models. Protein-protein interaction (PPI) networks were constructed by using GeneMANIA. Enrichment analysis is used to explore the signaling pathway regulated by MRPL18. Cell counting kit-8 (CCK-8) assays, colony formation, migration assays, flow cytometry, and xenograft models were employed to evaluate the role of MRPL18 in tumor progression. The immune response of MRPL18 was examined using correlation analysis. <b>Results:</b> High levels of MRPL18 are considered a risk factor in breast cancer. <i>In vitro</i> and <i>in vivo</i> studies demonstrated that MRPL18 promotes proliferation and migration in breast cancer. Besides, results found that MRPL18 promotes tumor growth through the activation of phosphatidylinositol 3-kinase (PI3K). Furthermore, high MRPL18 expression was linked to reduced immunotherapy efficacy, as indicated by correlations with immune checkpoints and immune-infiltrating patterns. <b>Conclusion:</b> MRPL18 promotes the progression of breast cancer.},
DOI = {10.32604/or.2025.065050}
}